The Study
Rosuvastatin reduces vascular inflammation and T cell and monocyte activation in HIV-infected subjects on antiretroviral therapy
This study gave one group of people a medicine and another group a sugar pill, then measured how their bodies changed. Because they randomly assigned who got what, we can say the medicine probably caused the changes they saw — like less inflammation. But it didn’t show if this makes people live longer or have fewer heart problems.
Analysis score
Maximum 90 for a randomized controlled trial.
Where the score came from
Even when HIV is controlled by medicine, the immune system stays overactive and can damage blood vessels. This study tested if a common cholesterol drug, rosuvastatin, could calm this overactivity.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 570 / 100
Quality score
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Yes — these changes are linked to lower risk of heart disease and immune failure in HIV, suggesting rosuvastatin may protect against long-term damage even when virus is suppressed.
- 2After 48 weeks, rosuvastatin lowered immune activation markers by 10–45% compared to placebo — including 41.6% fewer pro-inflammatory monocytes and 45% fewer exhausted T cells.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Journal of acquired immune deficiency syndromes (1999)
Year
2015
Authors
N. Funderburg, Ying Jiang, S. Debanne, Danielle E. Labbato, Steven M Juchnowski, B. Ferrari, B. Clagett, Janet K Robinson, M. Lederman, G. McComsey
Related Content
Claims (6)
In adults with HIV who are on effective antiretroviral treatment but still show signs of immune activation, taking 10 mg of rosuvastatin daily for 48 weeks reduces specific biomarkers of monocyte activation and vascular inflammation by defined percentages compared to no treatment.
In adults with HIV who are on antiretroviral therapy, taking 10 mg of rosuvastatin daily for 48 weeks reduces the percentage of activated CD4+ and CD8+ T cells by 38.1% and 44.8%, respectively, compared to a placebo.
In adults with HIV who are on antiretroviral therapy, taking rosuvastatin for 48 weeks at 10 mg daily lowers markers of T cell activation without changing LDL cholesterol levels, showing a direct anti-inflammatory effect.
In adults with HIV who are on effective antiretroviral treatment, taking 10 mg of rosuvastatin daily for 48 weeks lowers the percentage of a specific type of monocyte that expresses tissue factor by 41.6% compared to a placebo.
In adults with HIV who are on effective antiretroviral treatment, taking 10 mg of rosuvastatin daily for 48 weeks reduces the percentage of CD4+ and CD8+ T cells expressing PD-1 by 42.5% and 45.5%, respectively, compared to those taking a placebo.
Statins do not correct the core metabolic problems, persistent inflammation, or insulin resistance that cause cardiovascular disease.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.